Wound Management News

Vyjuvek was effective in healing the majority of dystrophic epidermolysis bullosa wounds in a phase 3 trial, Krystal Biotech announced in a press release.

A prediction model presented at ACR Convergence 2021 demonstrated that the use of platelet inhibitors could predict a lower probability of digital ulcer occurrence among patients with systemic sclerosis.

Individuals with recessive dystrophic epidermolysis bullosa who have larger wound sizes are more likely to have worsening skin disease severity and quality of life, according to a study.

Scars — whether from burns, injuries or other causes — can impact an individual’s life in many ways, and oftentimes these physical marks first appear in childhood.

So-called “COVID toes” and other cutaneous manifestations of the virus are not the only dermatologic challenges that a rheumatologist may face, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

A phase 3 trial showed the majority of burns treated with StrataGraft did not require autografting and achieved durable wound closure, Mallinckrodt announced in a press release.

Immunoglobulin A epidermolysis bullosa acquisita may be more common than previous data would indicate and is likely a separate entity from linear IgA bullous dermatosis, according to an investigation.

Diabetes and hyperlipidemia are both associated with granuloma annulare and may be risk factors for its development, according to a study.

Digital ulcers in patients with systemic sclerosis often need early assessment and systemic treatments, according to a review published in JAMA Dermatology.

StrataGraft, a bioengineered bilayer construct designed to mimic human skin, has been approved by the FDA for the treatment of thermal burns in which intact dermal elements remain and surgical intervention is indicated.